- Home
- TXO vs DNTH Comparison
TXO vs DNTH Comparison
Compare TXO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXO
- DNTH
- Stock Information
- Founded
- TXO 2012
- DNTH 2015
- Country
- TXO United States
- DNTH United States
- Employees
- TXO N/A
- DNTH N/A
- Industry
- TXO Oil & Gas Production
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- TXO Energy
- DNTH Health Care
- Exchange
- TXO Nasdaq
- DNTH Nasdaq
- Market Cap
- TXO 806.1M
- DNTH 657.0M
- IPO Year
- TXO 2023
- DNTH N/A
- Fundamental
- Price
- TXO $14.95
- DNTH $17.39
- Analyst Decision
- TXO
- DNTH Strong Buy
- Analyst Count
- TXO 0
- DNTH 8
- Target Price
- TXO N/A
- DNTH $53.00
- AVG Volume (30 Days)
- TXO 418.5K
- DNTH 255.5K
- Earning Date
- TXO 05-01-2025
- DNTH 05-12-2025
- Dividend Yield
- TXO 15.85%
- DNTH N/A
- EPS Growth
- TXO N/A
- DNTH N/A
- EPS
- TXO 0.40
- DNTH N/A
- Revenue
- TXO $299,696,000.00
- DNTH $6,524,000.00
- Revenue This Year
- TXO $19.72
- DNTH N/A
- Revenue Next Year
- TXO N/A
- DNTH N/A
- P/E Ratio
- TXO $37.06
- DNTH N/A
- Revenue Growth
- TXO 3.43
- DNTH 102.36
- 52 Week Low
- TXO $14.85
- DNTH $13.37
- 52 Week High
- TXO $22.39
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- TXO 29.28
- DNTH 35.86
- Support Level
- TXO $15.01
- DNTH $17.40
- Resistance Level
- TXO $15.74
- DNTH $18.45
- Average True Range (ATR)
- TXO 0.49
- DNTH 1.21
- MACD
- TXO -0.04
- DNTH -0.22
- Stochastic Oscillator
- TXO 3.28
- DNTH 10.60
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.